Market Survey on Pharmaceutical Caps and Closures Market Covering Sales Outlook, Up-to-date Key Trends, Market Size and Forecast, Per Capita Expenditure, Company Share, Brand Share, Regulations, Reimbursement Scenario, Epidemiology, Procedure Numbers, and Pipeline Assessment
An In-depth Market Insights of Pharmaceutical Caps and Closures Market including Screw Caps and Closure, Snap Caps and Closure, Push-Pull Caps and Closure, and Stopper and Seals Covering 30+ Countries like United States, United Kingdom, Germany, France, Norway, Sweden, Saudi Arabia, United Arab Emirates, Japan, Korea, Australia, New Zealand, and Others
Pharmaceutical Caps and Closures Market Outlook (2023 to 2033)
According to the latest Future Market Insights (FMI) report, the demand for pharmaceutical caps and closures is expected to flourish at a rate of 5.8% CAGR. In 2023, the market is expected to be valued at US$ 2,541.5 million. By the end of 2033, the market is projected to attain US$ 4,469.4 million.
How are Light Weight Packaging Formats Affecting the Pharmaceutical Caps and Closures Market?
Lightweight packaging materials have a high acceptance rate among consumers. Lightweight closures are made from resins, which result in low plastic usage while meeting the need for environment-friendly products.
Considering both economic and social benefits, lightweight packaging has become increasingly acceptable, while innovation and research are seen as a way to move forward in the market.
How are Investments in Product Development Influencing Growth?
Innovation in the field of plastic packaging has been aiding new product launches in the market. Researchers are focusing on the objective of reduction in development costs.
Extensive research has been conducted using samples from across the world to create unique products which are cost-friendly, profitable, and made with limited resources. For instance,
In March 2021, Drug Plastics & Glass Co Inc. filed a patent for new closure designs. The SecuRx Dosage Cap is ideal for cough syrups, antacids, vitamins, antibiotics, and cannabis beverages, and they deliver accurate, user-friendly liquid doses which can be produced in bulk at a lower cost. Innovations such as these are expected to have a positive impact on the market.
Attribute
Details
Pharmaceutical Caps and Closures Market Size (2023)
US$ 2,541.5 million
Pharmaceutical Caps and Closures Market Size (2033)
US$ 4,469.4 million
Pharmaceutical Caps and Closures Market CAGR (2023 to 2033)
5.8% CAGR
Pharmaceutical Caps and Closures Market CAGR (2018 to 2022)
5.1% CAGR
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
How are Stringent Regulations Hampering Market Growth?
Stringent rules and regulations associated with the grade of plastics used in end-use industries, especially in the food and beverages and pharmaceuticals industries might hamper market growth.
In the United States, regulations enacted by the Food and Drug Administration (FDA) have made it compulsory to implement child-resistant closures. This is projected to create key prospects for sales in the pharmaceutical industry.
Nevertheless, small firms might find it challenging to adhere to such stringent regulations. The machinery required for ascertaining stringent guidelines is often cost-intensive, which might discourage small players. This, in turn, can adversely affect the market.
Key Opportunities for Pharmaceutical Cap and Closure Manufacturers
Today, consumers are searching for products that are easy to access and use, with a high preference for self-resealing offerings. These factors are creating notable opportunities for manufacturers to develop consumer-friendly products.
Increasing investments in the healthcare sector in emerging countries are anticipated to boost the demand for pharmaceutical caps & closures. Local and regional players are expanding their distribution networks and manufacturing facilities to boost their business portfolios across the globe.
Increasing government initiatives for research and development is expected to provide significant opportunities in the pharmaceutical caps & closures market.
Find your sweet spots for generating winning opportunities in this market.
2018 to 2022 Pharmaceuticals Caps and Closures Market Outlook Compared to 2023 to 2033 Forecast
The production of pharmaceutical caps and closures was fairly limited, until recently, owing to a lack of awareness about safety concerns. According to Future Market Insights FMI), the sales of pharmaceutical caps and closures have grown at a 5.1% CAGR between 2018 and 2022.
The market gained momentum owing to accelerating demand for easy and safe packaging, leading to many innovations in the field. The demand for child-proof packaging owing to concerns over accidental consumption is rising. This is also expected to have a positive impact on the market.
A majority of children under five years are affected by unwanted harmful drugs owing to improper closing of containers as reported by the National Health Service (NHS).
With growing economies and the expansion of health care and insurance systems, the demand for pharmaceutical products is escalating strongly. It is predicted that the global pharmaceutical industry is projected to thrive at 3.6% annually in the coming years.
The demand in the market is projected to surge due to the growing emphasis on effective packaging to reduce the spoilage of pharmaceutical products and the probability of accidents. In the United States, the spending on medicines is increasing owing to new product adoption. Medical spending in Japan exceeded US$ 85 billion in 2019. The same for China touched US$ 136 billion.
The usage of medicines has jumped by 24% in 2020 as compared to 2015. Developed economies are projected to continue to use a large volume of prescribed medicines. Emerging countries are expected to use many generics and over-the-counter alternatives. With pharmaceutical spending consistently rising in developed countries, the demand for pharmaceutical caps and closures is expected to rise.
Future Market Insights expects the global pharmaceuticals caps and closures market to rise at 5.8% CAGR between 2023 and 2033.
Comparative View of the Pharmaceutical Caps and Closures Market
Pharmaceutical Caps and Closures Market:
Attributes
Pharmaceutical Caps and Closures Market
CAGR (2023 to 2033)
5.8%
Market Value (2033)
US$ 4,469.4 million
Opportunity
Manufacturers can capitalize on the increasing demand for consumer-friendly products that are easy to use and access and even have self-resealing capabilities.
Key Trends
Growing acceptance of lightweight packaging due to its social and economic benefits and continuous research and innovation in the market.
Compostable Plastic Packaging Material Market:
Attributes
Compostable Plastic Packaging Material Market
CAGR (2023 to 2033)
5.1%
Market Value (2033)
US$ 3.08 billion
Opportunity
Green-minded QSRs, cafeterias, catering services, and the food service sector are showing an inclination for bio-based plastic packaging. With the rise in sales in the F&B sector, bio-based plastic packaging can be greatly beneficial.
Key Trends
Increasing adoption of eco-friendly and sustainable packaging solutions is positively influencing market growth.
Biopharmaceuticals Packaging Market:
Attributes
Biopharmaceuticals Packaging Market
CAGR (2023 to 2033)
8.8%
Market Value (2033)
US$ 44 billion
Opportunity
Manufacturers are making investments in the vial forms in biopharmaceutical packaging to enhance their shelf life.
Key Trends
Increasing demand for glass-based biologics packaging is projected to influence market growth in the following years.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Country-wise Insights
How Significant is the Opportunity in the United States?
Country
The United States
Market Share % (2022)
26.5%
In the United States, the spending on medicines has steadily increased over the years, in turn driving the adoption of new caps and closure offerings. The United States is anticipated to hold over 89% of the pharmaceutical caps and closures market in North America. Also, regulations implemented by the FDA to ascertain child-resistant closures in the pharmaceutical industry have contributed to growth prospects.
Implementation of such laws is boosting research and development among manufacturers in North America. Additionally, the increasing occurrence of chronic disorders like cardiovascular disorders, cancer, and others is projected to fuel demand for various medications. This, in turn, is projected to fuel the demand for effective packaging in the pharmaceutical sector, creating opportunities for pharmaceutical caps and closure sales.
What are the Factors Driving Revenue Generation in the United Kingdom?
Country
The United Kingdom
CAGR % (2023 to 2033)
7.3%
The United Kingdom is projected to account for over 25% of Europe’s market through the assessment period ending in 2033. There are a few key factors speeding growth in the United Kingdom market for pharmaceutical caps and closures such as:
Common tech developments.
The demand for extensive product portfolios.
Improvements in drug development pipelines and production capacities.
Recent acquisitions have been propelled by the need to enlarge portfolios for non-exclusive clean injectables in the United Kingdom market. For instance,
In January 2020, Cyrano Berry launched its advanced molding technology to create extremely lightweight components, deliver reliable performance, safeguard product integrity, offer ease of drug administration, and improve patient safety.
What are the Factors Restricting Pharmaceutical Caps and Closure Production in Germany?
Country
Germany
Value Share % (2022)
4.8%
Germany’s market is projected to exhibit a 6.7% CAGR throughout the forecast period. Regulatory guidelines are relatively strict in Germany. As a result, achieving approvals is hard. The EMA guideline covers the exact requests for packaging materials that are in direct contact with pharma products or drugs.
Guidelines need to be met for new registration applications. As a result of stringent guidelines, elastomeric closures are increasingly used in injectable pharmaceutical products and delivery systems to ensure component functionality and suitability of parenteral products.
Plastic packaging systems create concerns associated with potential safety effects with the production of drugs and biopharmaceuticals. As a result, stringent regulation for all types of closures in Germany is restraining the market. Despite such restraints, the market is set to continue expanding in the years to follow due to the continuously spreading pharma industry.
Favorable Policies in Japan Driving the Market
Country
Japan
Market Share % (2022)
6.4%
Increasing expenditure on healthcare has enhanced the quality of healthcare while fortifying the demand for pharmaceutical products in countries like Japan. Japan’s market is expected to account for a significant share of the sales registered in the East Asia market in 2023.
In Japan, the total annual pharmaceutical spending equals US$ 93 billion. Moreover, the government of Japan provides for healthcare spending around 40% via national insurance schemes. Japan’s pharmaceutical sector has been forecasted to grow considerably in the coming years, paving the way for the expansion of the pharmaceutical caps and closures market.
What is the Scope of Growth of the Pharmaceutical Caps and Closures Market in Argentina?
Increasing investments in the healthcare sector are anticipated to boost the demand for pharmaceutical caps & closures. Increasing government initiatives for research and development is expected to provide significant opportunities in Argentina.
The market for pharmaceutical caps and closures in Argentina is exhibiting a 4% CAGR and is expected to account for more than 11% of Latin America’s market throughout the projection period. Encouraged by notable prospects, several market players are likely to expand their presence in the country. For Instance,
In September 2020, Bericap GmbH and Co KG established a new plant in Argentina and started a production facility in Malaysia as a hub for further expansion in Southeast Asia.
Category-wise Insights
Why is Child Resistant Driving Revenue by Functionality?
A relatively higher adoption rate is witnessed in child resistance closures owing to their effectiveness in preventing accidental consumption. The segment is expected to account for 61% market share in 2023.
Low costs of child resistance closures result in high revenue generation in the global pharmaceuticals caps and closures market. However, tamper-resistant products are estimated to reflect a higher rate of growth owing to concerns over counterfeiting.
What is the Market Share of Screw Caps and Closure?
Segment
Screw Caps & Closure
Value Share % (2022)
46.96%
Screw caps and closures are expected to continue to dominate the market during the forecast period. According to Future Market Insights, the segment is expected to hold around 46.96% of the market share through the end of 2033.
Screw caps and closures offer various benefits to manufacturers in the supply chain and are helpful in patient compliance. Besides this, they offer help in offering long shelf life and sustainability of products.
Why are Plastics Preferred for Pharmaceutical Caps and Closures?
Plastic closures are lightweight, cost-effective, and easy to manufacture which is expected to enable the plastic segment to account for over 60% of the market by the end of 2033. Lightweight packaging materials have high acceptance rates among consumers.
Lightweight closure made from resins results in low plastic usage while also complying with the recent rise in demand for environment-friendly products. The manufacturing cost is also reduced due to the usage of resin in lightweight caps. Therefore, considering both economic and social benefits, offering lightweight has become a key aspect of production. This is projected to also influence the material used for manufacturing pharmaceutical caps and closures.
How are Prescription (Rx) Caps and Closures Set to Fare?
Many pharmaceutical and biopharmaceutical drugs for chronic diseases are available only with prescriptions. As a result, prescribed drug closures are projected to account for a market share of 74.6% by the end of 2033.
Over-the-counter (OTC) alternatives are likely to witness increasing opportunities, especially in developing countries, owing to easy access to consumers. The trend is likely to continue in the upcoming years, fueling sales in the OTC segment.
How are Small Molecule Drug Modalities Contributing to Growth?
Most pharmaceutical companies are focusing on the development of small molecule and biopharmaceutical packaging with improved compatibility with container closure designs. This segment is estimated to value US$ 2.33 billion by the end of 2033. Research into biopharmaceuticals is also projected to create important growth opportunities.
Why are Pharmaceutical & Biotechnology Exhibiting High Demand for Pharmaceutical Caps and Closures?
Most pharma and biotech companies are focusing on pharma products with high brand awareness which is particularly true in developed countries. Pharmaceutical and biotechnology companies are likely to account for over 55% of sales in the market in 2023.
Which Therapeutic Class is Aiding in Increasing Sales of Pharmaceutical Caps and Closures?
Anticancer drugs currently lead the market in terms of therapeutic class, accounting for a share of over 20.5% in 2023. The increasing occurrence of cancer the world over is expected to fuel demand in the segment.
According to the IARC, by 2040, the world is expected to register 27.5 million new cancer cases and 17.3 million cancer deaths. According to the WHO, the chances of developing cancer before 75 years of age is about 20.2% and the risk of dying from cancer before the age of 75 years is about 10.6%.
The demand for cancer treatment medications is increasing at a significant speed, which is expected to create growth opportunities in the market. The demand for pharmaceutical caps and closures for anti-cancer drugs is forecasted to rise at a CAGR of 7.5% between 2023 and 2033.
Strategic Collaborations as a Key to Move Forward in the Pharmaceutical Caps and Closures Industry
Manufacturers in the pharmaceutical caps and closures market are primarily aiming to carry out strategic collaborations and research and development to consolidate growth in a competitive and fragmented market. For Instance,
In November 2019, MENSHEN Gmbh launched a new sustainable closure solution that was specially designed for the pharmaceutical industry.
In January 2020, Berry Group launched a new product Cyrano Berry’s advanced molding technology to create extremely lightweight components, which still deliver reliable performance to safeguard product integrity, ease drug administration, and improve patient safety.
In October 2020, West Pharmaceutical Services launched the Vial2Bag Advanced 20mm Admixture Device, which enables the reconstitution and transfer of a drug between a vial and an IV bag. The company is strategically making promotional plans for its established prescription brands to increase their awareness within the prescription market Its ‘Get Old’ campaign also makes a frequent appearance on the main company feeds and through its own Twitter and Facebook page.
Leading Firms in the Pharmaceutical Caps and Closures Market
Berry Global Inc.
Amcor Plc
Aptar, Inc.
Closure Systems International, Inc.
O.Berk Company, LLC
Bericap GmbH and Co KG
UNITED CAPS
CL Smith Company
Georg MENSHEN GmbH & Co. KG
WestRock Company
West Pharmaceutical Services, Inc
Drug Plastics & Glass Co Inc.
Gerresheimer AG
DWK Life Sciences GmbH
Parekhplast India Limited
Parshva Exim Limited
Scope of the Report
Attribute
Details
Forecast Period
2023 to 2033
Historical Data Available for
2018 to 2022
Market Analysis
US$ billion for Value
Key Regions Covered
North America, Latin America, Europe, East Asia, South Asia, Oceania Middle East & Africa
Key Countries Covered
The United States, Canada, Germany, the United Kingdom, France, Italy, Spain, Poland, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, South Africa
Key Segments Covered
Product Type, Functionality, Material Type, Availability, Drug Modality, Therapeutic Class, End Users, and Region
Pharmaceutical Caps and Closures Services Market by Category
Product Type:
Screw Caps & Closure
Snap Caps & Closure
Push-Pull Caps & Closure
Stopper & Seals
Others
Functionality:
Child Resistant
Tamper-evident
Material type:
Plastic
Elastomer
Metal
Availability:
Prescription (Rx) Pharmaceuticals
Over-the-Counter (OTC) Pharmaceuticals
Drug Modality:
Small Molecule (Synthetic Drugs)
Biopharmaceuticals
Therapeutic class:
Anticancer Drugs
Anti-infective Drugs
Anti-viral Drugs
Anti-bacterial Drugs
Anti-fungal Drugs
Others
Cardiovascular Drugs
Anti-inflammatory Drugs
Analgesics Drugs
Anti-diabetics
Ophthalmic Drugs
Neurological Drugs
Others
End Users:
Pharmaceutical & Biotechnology Companies
Contract Manufacturing Organizations (CMO)
Contract Research Organizations (CRO)
Academic & Research Institutes
Region:
North America
Latin America
Europe
East Asia
South Asia
Oceania
The Middle East and Africa (MEA)
Frequently Asked Questions
How much is the Pharmaceutical Caps and Closures Industry Projected to Attain by 2033 end?
The pharmaceutical caps and closures industry is projected to reach a valuation of US$ 4,469.4 million by 2033.
Which are the Top Companies Providing Pharmaceutical Caps and Closures?
Berry Global Inc. and Amcor Plc are the top players in the pharmaceutical caps and closures industry.
Which Country is Expected to Account for a Significant Market Share?
The United States is projected to hold a sizeable market share over the forecast period.
At what CAGR is the Pharmaceutical Caps and Closures Industry Projected to Expand in the Forecast Period?
The pharmaceutical caps and closures industry is projected to expand at a CAGR of 5.8%.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Billion) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Billion) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Billion) Analysis By Product type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Billion) Analysis and Forecast By Product type, 2023 to 2033
5.3.1. Screw Caps & Closure
5.3.2. Snap Caps & Closure
5.3.3. Push-Pull Caps & Closure
5.3.4. Stopper & Seals
5.3.5. Others
5.4. Y-o-Y Growth Trend Analysis By Product type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Product type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Functionality
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Billion) Analysis By Functionality, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Billion) Analysis and Forecast By Functionality, 2023 to 2033
6.3.1. Child Resistant
6.3.2. Tamper-evident
6.4. Y-o-Y Growth Trend Analysis By Functionality, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Functionality, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Material type
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Billion) Analysis By Material type, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Billion) Analysis and Forecast By Material type, 2023 to 2033
7.3.1. Plastic
7.3.2. Elastomer
7.3.3. Metal
7.4. Y-o-Y Growth Trend Analysis By Material type, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Material type, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Avalability
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Billion) Analysis By Avalability, 2018 to 2022
8.3. Current and Future Market Size Value (US$ Billion) Analysis and Forecast By Avalability, 2023 to 2033
8.3.1. Prescription (Rx) Pharmaceuticals
8.3.2. "Over-the-Counter (OTC) Pharmaceuticals"
8.4. Y-o-Y Growth Trend Analysis By Avalability, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By Avalability, 2023 to 2033
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Modality
9.1. Introduction / Key Findings
9.2. Historical Market Size Value (US$ Billion) Analysis By Drug Modality, 2018 to 2022
9.3. Current and Future Market Size Value (US$ Billion) Analysis and Forecast By Drug Modality, 2023 to 2033
9.3.1. Small Molecule (Synthetic Drugs)
9.3.2. Biopharmaceuticals
9.4. Y-o-Y Growth Trend Analysis By Drug Modality, 2018 to 2022
9.5. Absolute $ Opportunity Analysis By Drug Modality, 2023 to 2033
10. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Therapeutic class
10.1. Introduction / Key Findings
10.2. Historical Market Size Value (US$ Billion) Analysis By Therapeutic class, 2018 to 2022
10.3. Current and Future Market Size Value (US$ Billion) Analysis and Forecast By Therapeutic class, 2023 to 2033
10.3.1. Anticancer Drugs
10.3.2. Anti-infective Drugs
10.3.3. Anti-viral Drugs
10.3.4. Anti-bacterial Drugs
10.3.5. Anti-fungal Drugs
10.3.6. Cardiovascular Drugs
10.3.7. Anti-inflammatory Drugs
10.3.8. Analgesics Drugs
10.3.9. Anti-diabetics
10.3.10. Ophthalmic Drugs
10.3.11. Neurological Drugs
10.4. Y-o-Y Growth Trend Analysis By Therapeutic class, 2018 to 2022
10.5. Absolute $ Opportunity Analysis By Therapeutic class, 2023 to 2033
11. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Neurological Drugs
11.1. Introduction / Key Findings
11.2. Historical Market Size Value (US$ Billion) Analysis By Neurological Drugs, 2018 to 2022
11.3. Current and Future Market Size Value (US$ Billion) Analysis and Forecast By Neurological Drugs, 2023 to 2033
11.3.1. Pharmaceutical & Biotechnology Companies
11.3.2. Contract Manufacturing Organizations (CMO)
11.3.3. Contract Research Organizations (CRO)
11.3.4. Academic & Research Institutes
11.4. Y-o-Y Growth Trend Analysis By Neurological Drugs, 2018 to 2022
11.5. Absolute $ Opportunity Analysis By Neurological Drugs, 2023 to 2033
12. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
12.1. Introduction
12.2. Historical Market Size Value (US$ Billion) Analysis By Region, 2018 to 2022
12.3. Current Market Size Value (US$ Billion) Analysis and Forecast By Region, 2023 to 2033
12.3.1. North America
12.3.2. Latin America
12.3.3. Western Europe
12.3.4. Eastern Europe
12.3.5. South Asia and Pacific
12.3.6. East Asia
12.3.7. Middle East and Africa
12.4. Market Attractiveness Analysis By Region
13. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. The USA
13.2.1.2. Canada
13.2.2. By Product type
13.2.3. By Functionality
13.2.4. By Material type
13.2.5. By Avalability
13.2.6. By Drug Modality
13.2.7. By Therapeutic class
13.2.8. By Neurological Drugs
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Product type
13.3.3. By Functionality
13.3.4. By Material type
13.3.5. By Avalability
13.3.6. By Drug Modality
13.3.7. By Therapeutic class
13.3.8. By Neurological Drugs
13.4. Key Takeaways
14. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. Brazil
14.2.1.2. Mexico
14.2.1.3. Rest of Latin America
14.2.2. By Product type
14.2.3. By Functionality
14.2.4. By Material type
14.2.5. By Avalability
14.2.6. By Drug Modality
14.2.7. By Therapeutic class
14.2.8. By Neurological Drugs
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Product type
14.3.3. By Functionality
14.3.4. By Material type
14.3.5. By Avalability
14.3.6. By Drug Modality
14.3.7. By Therapeutic class
14.3.8. By Neurological Drugs
14.4. Key Takeaways
15. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. Germany
15.2.1.2. United Kingdom
15.2.1.3. France
15.2.1.4. Spain
15.2.1.5. Italy
15.2.1.6. Rest of Western Europe
15.2.2. By Product type
15.2.3. By Functionality
15.2.4. By Material type
15.2.5. By Avalability
15.2.6. By Drug Modality
15.2.7. By Therapeutic class
15.2.8. By Neurological Drugs
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Product type
15.3.3. By Functionality
15.3.4. By Material type
15.3.5. By Avalability
15.3.6. By Drug Modality
15.3.7. By Therapeutic class
15.3.8. By Neurological Drugs
15.4. Key Takeaways
16. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
16.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
16.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
16.2.1. By Country
16.2.1.1. Poland
16.2.1.2. Russia
16.2.1.3. Czech Republic
16.2.1.4. Romania
16.2.1.5. Rest of Eastern Europe
16.2.2. By Product type
16.2.3. By Functionality
16.2.4. By Material type
16.2.5. By Avalability
16.2.6. By Drug Modality
16.2.7. By Therapeutic class
16.2.8. By Neurological Drugs
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Product type
16.3.3. By Functionality
16.3.4. By Material type
16.3.5. By Avalability
16.3.6. By Drug Modality
16.3.7. By Therapeutic class
16.3.8. By Neurological Drugs
16.4. Key Takeaways
17. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
17.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
17.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
17.2.1. By Country
17.2.1.1. India
17.2.1.2. Bangladesh
17.2.1.3. Australia
17.2.1.4. New Zealand
17.2.1.5. Rest of South Asia and Pacific
17.2.2. By Product type
17.2.3. By Functionality
17.2.4. By Material type
17.2.5. By Avalability
17.2.6. By Drug Modality
17.2.7. By Therapeutic class
17.2.8. By Neurological Drugs
17.3. Market Attractiveness Analysis
17.3.1. By Country
17.3.2. By Product type
17.3.3. By Functionality
17.3.4. By Material type
17.3.5. By Avalability
17.3.6. By Drug Modality
17.3.7. By Therapeutic class
17.3.8. By Neurological Drugs
17.4. Key Takeaways
18. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
18.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
18.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
18.2.1. By Country
18.2.1.1. China
18.2.1.2. Japan
18.2.1.3. South Korea
18.2.2. By Product type
18.2.3. By Functionality
18.2.4. By Material type
18.2.5. By Avalability
18.2.6. By Drug Modality
18.2.7. By Therapeutic class
18.2.8. By Neurological Drugs
18.3. Market Attractiveness Analysis
18.3.1. By Country
18.3.2. By Product type
18.3.3. By Functionality
18.3.4. By Material type
18.3.5. By Avalability
18.3.6. By Drug Modality
18.3.7. By Therapeutic class
18.3.8. By Neurological Drugs
18.4. Key Takeaways
19. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
19.1. Historical Market Size Value (US$ Billion) Trend Analysis By Market Taxonomy, 2018 to 2022
19.2. Market Size Value (US$ Billion) Forecast By Market Taxonomy, 2023 to 2033
19.2.1. By Country
19.2.1.1. GCC Countries
19.2.1.2. South Africa
19.2.1.3. Israel
19.2.1.4. Rest of MEA
19.2.2. By Product type
19.2.3. By Functionality
19.2.4. By Material type
19.2.5. By Avalability
19.2.6. By Drug Modality
19.2.7. By Therapeutic class
19.2.8. By Neurological Drugs
19.3. Market Attractiveness Analysis
19.3.1. By Country
19.3.2. By Product type
19.3.3. By Functionality
19.3.4. By Material type
19.3.5. By Avalability
19.3.6. By Drug Modality
19.3.7. By Therapeutic class
19.3.8. By Neurological Drugs
19.4. Key Takeaways
20. Key Countries Market Analysis
20.1. USA
20.1.1. Pricing Analysis
20.1.2. Market Share Analysis, 2022
20.1.2.1. By Product type
20.1.2.2. By Functionality
20.1.2.3. By Material type
20.1.2.4. By Avalability
20.1.2.5. By Drug Modality
20.1.2.6. By Therapeutic class
20.1.2.7. By Neurological Drugs
20.2. Canada
20.2.1. Pricing Analysis
20.2.2. Market Share Analysis, 2022
20.2.2.1. By Product type
20.2.2.2. By Functionality
20.2.2.3. By Material type
20.2.2.4. By Avalability
20.2.2.5. By Drug Modality
20.2.2.6. By Therapeutic class
20.2.2.7. By Neurological Drugs
20.3. Brazil
20.3.1. Pricing Analysis
20.3.2. Market Share Analysis, 2022
20.3.2.1. By Product type
20.3.2.2. By Functionality
20.3.2.3. By Material type
20.3.2.4. By Avalability
20.3.2.5. By Drug Modality
20.3.2.6. By Therapeutic class
20.3.2.7. By Neurological Drugs
20.4. Mexico
20.4.1. Pricing Analysis
20.4.2. Market Share Analysis, 2022
20.4.2.1. By Product type
20.4.2.2. By Functionality
20.4.2.3. By Material type
20.4.2.4. By Avalability
20.4.2.5. By Drug Modality
20.4.2.6. By Therapeutic class
20.4.2.7. By Neurological Drugs
20.5. Germany
20.5.1. Pricing Analysis
20.5.2. Market Share Analysis, 2022
20.5.2.1. By Product type
20.5.2.2. By Functionality
20.5.2.3. By Material type
20.5.2.4. By Avalability
20.5.2.5. By Drug Modality
20.5.2.6. By Therapeutic class
20.5.2.7. By Neurological Drugs
20.6. United Kingdom
20.6.1. Pricing Analysis
20.6.2. Market Share Analysis, 2022
20.6.2.1. By Product type
20.6.2.2. By Functionality
20.6.2.3. By Material type
20.6.2.4. By Avalability
20.6.2.5. By Drug Modality
20.6.2.6. By Therapeutic class
20.6.2.7. By Neurological Drugs
20.7. France
20.7.1. Pricing Analysis
20.7.2. Market Share Analysis, 2022
20.7.2.1. By Product type
20.7.2.2. By Functionality
20.7.2.3. By Material type
20.7.2.4. By Avalability
20.7.2.5. By Drug Modality
20.7.2.6. By Therapeutic class
20.7.2.7. By Neurological Drugs
20.8. Spain
20.8.1. Pricing Analysis
20.8.2. Market Share Analysis, 2022
20.8.2.1. By Product type
20.8.2.2. By Functionality
20.8.2.3. By Material type
20.8.2.4. By Avalability
20.8.2.5. By Drug Modality
20.8.2.6. By Therapeutic class
20.8.2.7. By Neurological Drugs
20.9. Italy
20.9.1. Pricing Analysis
20.9.2. Market Share Analysis, 2022
20.9.2.1. By Product type
20.9.2.2. By Functionality
20.9.2.3. By Material type
20.9.2.4. By Avalability
20.9.2.5. By Drug Modality
20.9.2.6. By Therapeutic class
20.9.2.7. By Neurological Drugs
20.10. Poland
20.10.1. Pricing Analysis
20.10.2. Market Share Analysis, 2022
20.10.2.1. By Product type
20.10.2.2. By Functionality
20.10.2.3. By Material type
20.10.2.4. By Avalability
20.10.2.5. By Drug Modality
20.10.2.6. By Therapeutic class
20.10.2.7. By Neurological Drugs
20.11. Russia
20.11.1. Pricing Analysis
20.11.2. Market Share Analysis, 2022
20.11.2.1. By Product type
20.11.2.2. By Functionality
20.11.2.3. By Material type
20.11.2.4. By Avalability
20.11.2.5. By Drug Modality
20.11.2.6. By Therapeutic class
20.11.2.7. By Neurological Drugs
20.12. Czech Republic
20.12.1. Pricing Analysis
20.12.2. Market Share Analysis, 2022
20.12.2.1. By Product type
20.12.2.2. By Functionality
20.12.2.3. By Material type
20.12.2.4. By Avalability
20.12.2.5. By Drug Modality
20.12.2.6. By Therapeutic class
20.12.2.7. By Neurological Drugs
20.13. Romania
20.13.1. Pricing Analysis
20.13.2. Market Share Analysis, 2022
20.13.2.1. By Product type
20.13.2.2. By Functionality
20.13.2.3. By Material type
20.13.2.4. By Avalability
20.13.2.5. By Drug Modality
20.13.2.6. By Therapeutic class
20.13.2.7. By Neurological Drugs
20.14. India
20.14.1. Pricing Analysis
20.14.2. Market Share Analysis, 2022
20.14.2.1. By Product type
20.14.2.2. By Functionality
20.14.2.3. By Material type
20.14.2.4. By Avalability
20.14.2.5. By Drug Modality
20.14.2.6. By Therapeutic class
20.14.2.7. By Neurological Drugs
20.15. Bangladesh
20.15.1. Pricing Analysis
20.15.2. Market Share Analysis, 2022
20.15.2.1. By Product type
20.15.2.2. By Functionality
20.15.2.3. By Material type
20.15.2.4. By Avalability
20.15.2.5. By Drug Modality
20.15.2.6. By Therapeutic class
20.15.2.7. By Neurological Drugs
20.16. Australia
20.16.1. Pricing Analysis
20.16.2. Market Share Analysis, 2022
20.16.2.1. By Product type
20.16.2.2. By Functionality
20.16.2.3. By Material type
20.16.2.4. By Avalability
20.16.2.5. By Drug Modality
20.16.2.6. By Therapeutic class
20.16.2.7. By Neurological Drugs
20.17. New Zealand
20.17.1. Pricing Analysis
20.17.2. Market Share Analysis, 2022
20.17.2.1. By Product type
20.17.2.2. By Functionality
20.17.2.3. By Material type
20.17.2.4. By Avalability
20.17.2.5. By Drug Modality
20.17.2.6. By Therapeutic class
20.17.2.7. By Neurological Drugs
20.18. China
20.18.1. Pricing Analysis
20.18.2. Market Share Analysis, 2022
20.18.2.1. By Product type
20.18.2.2. By Functionality
20.18.2.3. By Material type
20.18.2.4. By Avalability
20.18.2.5. By Drug Modality
20.18.2.6. By Therapeutic class
20.18.2.7. By Neurological Drugs
20.19. Japan
20.19.1. Pricing Analysis
20.19.2. Market Share Analysis, 2022
20.19.2.1. By Product type
20.19.2.2. By Functionality
20.19.2.3. By Material type
20.19.2.4. By Avalability
20.19.2.5. By Drug Modality
20.19.2.6. By Therapeutic class
20.19.2.7. By Neurological Drugs
20.20. South Korea
20.20.1. Pricing Analysis
20.20.2. Market Share Analysis, 2022
20.20.2.1. By Product type
20.20.2.2. By Functionality
20.20.2.3. By Material type
20.20.2.4. By Avalability
20.20.2.5. By Drug Modality
20.20.2.6. By Therapeutic class
20.20.2.7. By Neurological Drugs
20.21. GCC Countries
20.21.1. Pricing Analysis
20.21.2. Market Share Analysis, 2022
20.21.2.1. By Product type
20.21.2.2. By Functionality
20.21.2.3. By Material type
20.21.2.4. By Avalability
20.21.2.5. By Drug Modality
20.21.2.6. By Therapeutic class
20.21.2.7. By Neurological Drugs
20.22. South Africa
20.22.1. Pricing Analysis
20.22.2. Market Share Analysis, 2022
20.22.2.1. By Product type
20.22.2.2. By Functionality
20.22.2.3. By Material type
20.22.2.4. By Avalability
20.22.2.5. By Drug Modality
20.22.2.6. By Therapeutic class
20.22.2.7. By Neurological Drugs
20.23. Israel
20.23.1. Pricing Analysis
20.23.2. Market Share Analysis, 2022
20.23.2.1. By Product type
20.23.2.2. By Functionality
20.23.2.3. By Material type
20.23.2.4. By Avalability
20.23.2.5. By Drug Modality
20.23.2.6. By Therapeutic class
20.23.2.7. By Neurological Drugs
21. Market Structure Analysis
21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Market Share Analysis of Top Players
21.3.1. By Regional
21.3.2. By Product type
21.3.3. By Functionality
21.3.4. By Material type
21.3.5. By Avalability
21.3.6. By Drug Modality
21.3.7. By Therapeutic class
21.3.8. By Neurological Drugs
22. Competition Analysis
22.1. Competition Deep Dive
22.1.1. Berry Global Inc
22.1.1.1. Overview
22.1.1.2. Product Portfolio
22.1.1.3. Profitability by Market Segments
22.1.1.4. Sales Footprint
22.1.1.5. Strategy Overview
22.1.1.5.1. Marketing Strategy
22.1.2. Amcor Plc
22.1.2.1. Overview
22.1.2.2. Product Portfolio
22.1.2.3. Profitability by Market Segments
22.1.2.4. Sales Footprint
22.1.2.5. Strategy Overview
22.1.2.5.1. Marketing Strategy
22.1.3. Aptar, Inc.
22.1.3.1. Overview
22.1.3.2. Product Portfolio
22.1.3.3. Profitability by Market Segments
22.1.3.4. Sales Footprint
22.1.3.5. Strategy Overview
22.1.3.5.1. Marketing Strategy
22.1.4. Closure Systems International, Inc.
22.1.4.1. Overview
22.1.4.2. Product Portfolio
22.1.4.3. Profitability by Market Segments
22.1.4.4. Sales Footprint
22.1.4.5. Strategy Overview
22.1.4.5.1. Marketing Strategy
22.1.5. O.Berk Company, LLC
22.1.5.1. Overview
22.1.5.2. Product Portfolio
22.1.5.3. Profitability by Market Segments
22.1.5.4. Sales Footprint
22.1.5.5. Strategy Overview
22.1.5.5.1. Marketing Strategy
22.1.6. Bericap GmbH and Co KG
22.1.6.1. Overview
22.1.6.2. Product Portfolio
22.1.6.3. Profitability by Market Segments
22.1.6.4. Sales Footprint
22.1.6.5. Strategy Overview
22.1.6.5.1. Marketing Strategy
22.1.7. UNITED CAPS
22.1.7.1. Overview
22.1.7.2. Product Portfolio
22.1.7.3. Profitability by Market Segments
22.1.7.4. Sales Footprint
22.1.7.5. Strategy Overview
22.1.7.5.1. Marketing Strategy
22.1.8. CL Smith Company
22.1.8.1. Overview
22.1.8.2. Product Portfolio
22.1.8.3. Profitability by Market Segments
22.1.8.4. Sales Footprint
22.1.8.5. Strategy Overview
22.1.8.5.1. Marketing Strategy
22.1.9. Georg MENSHEN GmbH & Co. KG
22.1.9.1. Overview
22.1.9.2. Product Portfolio
22.1.9.3. Profitability by Market Segments
22.1.9.4. Sales Footprint
22.1.9.5. Strategy Overview
22.1.9.5.1. Marketing Strategy
22.1.10. WestRock Company
22.1.10.1. Overview
22.1.10.2. Product Portfolio
22.1.10.3. Profitability by Market Segments
22.1.10.4. Sales Footprint
22.1.10.5. Strategy Overview
22.1.10.5.1. Marketing Strategy
22.1.11. West Pharmaceutical Services, Inc
22.1.11.1. Overview
22.1.11.2. Product Portfolio
22.1.11.3. Profitability by Market Segments
22.1.11.4. Sales Footprint
22.1.11.5. Strategy Overview
22.1.11.5.1. Marketing Strategy
22.1.12. Drug Plastics & Glass Co Inc.
22.1.12.1. Overview
22.1.12.2. Product Portfolio
22.1.12.3. Profitability by Market Segments
22.1.12.4. Sales Footprint
22.1.12.5. Strategy Overview
22.1.12.5.1. Marketing Strategy
22.1.13. Gerresheimer AG
22.1.13.1. Overview
22.1.13.2. Product Portfolio
22.1.13.3. Profitability by Market Segments
22.1.13.4. Sales Footprint
22.1.13.5. Strategy Overview
22.1.13.5.1. Marketing Strategy
22.1.14. DWK Life Sciences GmbH
22.1.14.1. Overview
22.1.14.2. Product Portfolio
22.1.14.3. Profitability by Market Segments
22.1.14.4. Sales Footprint
22.1.14.5. Strategy Overview
22.1.14.5.1. Marketing Strategy
22.1.15. Parekhplast India Limited
22.1.15.1. Overview
22.1.15.2. Product Portfolio
22.1.15.3. Profitability by Market Segments
22.1.15.4. Sales Footprint
22.1.15.5. Strategy Overview
22.1.15.5.1. Marketing Strategy
22.1.16. Parshva Exim Limited
22.1.16.1. Overview
22.1.16.2. Product Portfolio
22.1.16.3. Profitability by Market Segments
22.1.16.4. Sales Footprint
22.1.16.5. Strategy Overview
22.1.16.5.1. Marketing Strategy
23. Assumptions & Acronyms Used24. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Billion) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Billion) Forecast by Product type, 2018 to 2033
Table 3: Global Market Value (US$ Billion) Forecast by Functionality, 2018 to 2033
Table 4: Global Market Value (US$ Billion) Forecast by Material type, 2018 to 2033
Table 5: Global Market Value (US$ Billion) Forecast by Avalability, 2018 to 2033
Table 6: Global Market Value (US$ Billion) Forecast by Drug Modality, 2018 to 2033
Table 7: Global Market Value (US$ Billion) Forecast by Therapeutic class, 2018 to 2033
Table 8: Global Market Value (US$ Billion) Forecast by Neurological Drugs, 2018 to 2033
Table 9: North America Market Value (US$ Billion) Forecast by Country, 2018 to 2033
Table 10: North America Market Value (US$ Billion) Forecast by Product type, 2018 to 2033
Table 11: North America Market Value (US$ Billion) Forecast by Functionality, 2018 to 2033
Table 12: North America Market Value (US$ Billion) Forecast by Material type, 2018 to 2033
Table 13: North America Market Value (US$ Billion) Forecast by Avalability, 2018 to 2033
Table 14: North America Market Value (US$ Billion) Forecast by Drug Modality, 2018 to 2033
Table 15: North America Market Value (US$ Billion) Forecast by Therapeutic class, 2018 to 2033
Table 16: North America Market Value (US$ Billion) Forecast by Neurological Drugs, 2018 to 2033
Table 17: Latin America Market Value (US$ Billion) Forecast by Country, 2018 to 2033
Table 18: Latin America Market Value (US$ Billion) Forecast by Product type, 2018 to 2033
Table 19: Latin America Market Value (US$ Billion) Forecast by Functionality, 2018 to 2033
Table 20: Latin America Market Value (US$ Billion) Forecast by Material type, 2018 to 2033
Table 21: Latin America Market Value (US$ Billion) Forecast by Avalability, 2018 to 2033
Table 22: Latin America Market Value (US$ Billion) Forecast by Drug Modality, 2018 to 2033
Table 23: Latin America Market Value (US$ Billion) Forecast by Therapeutic class, 2018 to 2033
Table 24: Latin America Market Value (US$ Billion) Forecast by Neurological Drugs, 2018 to 2033
Table 25: Western Europe Market Value (US$ Billion) Forecast by Country, 2018 to 2033
Table 26: Western Europe Market Value (US$ Billion) Forecast by Product type, 2018 to 2033
Table 27: Western Europe Market Value (US$ Billion) Forecast by Functionality, 2018 to 2033
Table 28: Western Europe Market Value (US$ Billion) Forecast by Material type, 2018 to 2033
Table 29: Western Europe Market Value (US$ Billion) Forecast by Avalability, 2018 to 2033
Table 30: Western Europe Market Value (US$ Billion) Forecast by Drug Modality, 2018 to 2033
Table 31: Western Europe Market Value (US$ Billion) Forecast by Therapeutic class, 2018 to 2033
Table 32: Western Europe Market Value (US$ Billion) Forecast by Neurological Drugs, 2018 to 2033
Table 33: Eastern Europe Market Value (US$ Billion) Forecast by Country, 2018 to 2033
Table 34: Eastern Europe Market Value (US$ Billion) Forecast by Product type, 2018 to 2033
Table 35: Eastern Europe Market Value (US$ Billion) Forecast by Functionality, 2018 to 2033
Table 36: Eastern Europe Market Value (US$ Billion) Forecast by Material type, 2018 to 2033
Table 37: Eastern Europe Market Value (US$ Billion) Forecast by Avalability, 2018 to 2033
Table 38: Eastern Europe Market Value (US$ Billion) Forecast by Drug Modality, 2018 to 2033
Table 39: Eastern Europe Market Value (US$ Billion) Forecast by Therapeutic class, 2018 to 2033
Table 40: Eastern Europe Market Value (US$ Billion) Forecast by Neurological Drugs, 2018 to 2033
Table 41: South Asia and Pacific Market Value (US$ Billion) Forecast by Country, 2018 to 2033
Table 42: South Asia and Pacific Market Value (US$ Billion) Forecast by Product type, 2018 to 2033
Table 43: South Asia and Pacific Market Value (US$ Billion) Forecast by Functionality, 2018 to 2033
Table 44: South Asia and Pacific Market Value (US$ Billion) Forecast by Material type, 2018 to 2033
Table 45: South Asia and Pacific Market Value (US$ Billion) Forecast by Avalability, 2018 to 2033
Table 46: South Asia and Pacific Market Value (US$ Billion) Forecast by Drug Modality, 2018 to 2033
Table 47: South Asia and Pacific Market Value (US$ Billion) Forecast by Therapeutic class, 2018 to 2033
Table 48: South Asia and Pacific Market Value (US$ Billion) Forecast by Neurological Drugs, 2018 to 2033
Table 49: East Asia Market Value (US$ Billion) Forecast by Country, 2018 to 2033
Table 50: East Asia Market Value (US$ Billion) Forecast by Product type, 2018 to 2033
Table 51: East Asia Market Value (US$ Billion) Forecast by Functionality, 2018 to 2033
Table 52: East Asia Market Value (US$ Billion) Forecast by Material type, 2018 to 2033
Table 53: East Asia Market Value (US$ Billion) Forecast by Avalability, 2018 to 2033
Table 54: East Asia Market Value (US$ Billion) Forecast by Drug Modality, 2018 to 2033
Table 55: East Asia Market Value (US$ Billion) Forecast by Therapeutic class, 2018 to 2033
Table 56: East Asia Market Value (US$ Billion) Forecast by Neurological Drugs, 2018 to 2033
Table 57: Middle East and Africa Market Value (US$ Billion) Forecast by Country, 2018 to 2033
Table 58: Middle East and Africa Market Value (US$ Billion) Forecast by Product type, 2018 to 2033
Table 59: Middle East and Africa Market Value (US$ Billion) Forecast by Functionality, 2018 to 2033
Table 60: Middle East and Africa Market Value (US$ Billion) Forecast by Material type, 2018 to 2033
Table 61: Middle East and Africa Market Value (US$ Billion) Forecast by Avalability, 2018 to 2033
Table 62: Middle East and Africa Market Value (US$ Billion) Forecast by Drug Modality, 2018 to 2033
Table 63: Middle East and Africa Market Value (US$ Billion) Forecast by Therapeutic class, 2018 to 2033
Table 64: Middle East and Africa Market Value (US$ Billion) Forecast by Neurological Drugs, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Billion) by Product type, 2023 to 2033
Figure 2: Global Market Value (US$ Billion) by Functionality, 2023 to 2033
Figure 3: Global Market Value (US$ Billion) by Material type, 2023 to 2033
Figure 4: Global Market Value (US$ Billion) by Avalability, 2023 to 2033
Figure 5: Global Market Value (US$ Billion) by Drug Modality, 2023 to 2033
Figure 6: Global Market Value (US$ Billion) by Therapeutic class, 2023 to 2033
Figure 7: Global Market Value (US$ Billion) by Neurological Drugs, 2023 to 2033
Figure 8: Global Market Value (US$ Billion) by Region, 2023 to 2033
Figure 9: Global Market Value (US$ Billion) Analysis by Region, 2018 to 2033
Figure 10: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 11: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 12: Global Market Value (US$ Billion) Analysis by Product type, 2018 to 2033
Figure 13: Global Market Value Share (%) and BPS Analysis by Product type, 2023 to 2033
Figure 14: Global Market Y-o-Y Growth (%) Projections by Product type, 2023 to 2033
Figure 15: Global Market Value (US$ Billion) Analysis by Functionality, 2018 to 2033
Figure 16: Global Market Value Share (%) and BPS Analysis by Functionality, 2023 to 2033
Figure 17: Global Market Y-o-Y Growth (%) Projections by Functionality, 2023 to 2033
Figure 18: Global Market Value (US$ Billion) Analysis by Material type, 2018 to 2033
Figure 19: Global Market Value Share (%) and BPS Analysis by Material type, 2023 to 2033
Figure 20: Global Market Y-o-Y Growth (%) Projections by Material type, 2023 to 2033
Figure 21: Global Market Value (US$ Billion) Analysis by Avalability, 2018 to 2033
Figure 22: Global Market Value Share (%) and BPS Analysis by Avalability, 2023 to 2033
Figure 23: Global Market Y-o-Y Growth (%) Projections by Avalability, 2023 to 2033
Figure 24: Global Market Value (US$ Billion) Analysis by Drug Modality, 2018 to 2033
Figure 25: Global Market Value Share (%) and BPS Analysis by Drug Modality, 2023 to 2033
Figure 26: Global Market Y-o-Y Growth (%) Projections by Drug Modality, 2023 to 2033
Figure 27: Global Market Value (US$ Billion) Analysis by Therapeutic class, 2018 to 2033
Figure 28: Global Market Value Share (%) and BPS Analysis by Therapeutic class, 2023 to 2033
Figure 29: Global Market Y-o-Y Growth (%) Projections by Therapeutic class, 2023 to 2033
Figure 30: Global Market Value (US$ Billion) Analysis by Neurological Drugs, 2018 to 2033
Figure 31: Global Market Value Share (%) and BPS Analysis by Neurological Drugs, 2023 to 2033
Figure 32: Global Market Y-o-Y Growth (%) Projections by Neurological Drugs, 2023 to 2033
Figure 33: Global Market Attractiveness by Product type, 2023 to 2033
Figure 34: Global Market Attractiveness by Functionality, 2023 to 2033
Figure 35: Global Market Attractiveness by Material type, 2023 to 2033
Figure 36: Global Market Attractiveness by Avalability, 2023 to 2033
Figure 37: Global Market Attractiveness by Drug Modality, 2023 to 2033
Figure 38: Global Market Attractiveness by Therapeutic class, 2023 to 2033
Figure 39: Global Market Attractiveness by Neurological Drugs, 2023 to 2033
Figure 40: Global Market Attractiveness by Region, 2023 to 2033
Figure 41: North America Market Value (US$ Billion) by Product type, 2023 to 2033
Figure 42: North America Market Value (US$ Billion) by Functionality, 2023 to 2033
Figure 43: North America Market Value (US$ Billion) by Material type, 2023 to 2033
Figure 44: North America Market Value (US$ Billion) by Avalability, 2023 to 2033
Figure 45: North America Market Value (US$ Billion) by Drug Modality, 2023 to 2033
Figure 46: North America Market Value (US$ Billion) by Therapeutic class, 2023 to 2033
Figure 47: North America Market Value (US$ Billion) by Neurological Drugs, 2023 to 2033
Figure 48: North America Market Value (US$ Billion) by Country, 2023 to 2033
Figure 49: North America Market Value (US$ Billion) Analysis by Country, 2018 to 2033
Figure 50: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 51: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 52: North America Market Value (US$ Billion) Analysis by Product type, 2018 to 2033
Figure 53: North America Market Value Share (%) and BPS Analysis by Product type, 2023 to 2033
Figure 54: North America Market Y-o-Y Growth (%) Projections by Product type, 2023 to 2033
Figure 55: North America Market Value (US$ Billion) Analysis by Functionality, 2018 to 2033
Figure 56: North America Market Value Share (%) and BPS Analysis by Functionality, 2023 to 2033
Figure 57: North America Market Y-o-Y Growth (%) Projections by Functionality, 2023 to 2033
Figure 58: North America Market Value (US$ Billion) Analysis by Material type, 2018 to 2033
Figure 59: North America Market Value Share (%) and BPS Analysis by Material type, 2023 to 2033
Figure 60: North America Market Y-o-Y Growth (%) Projections by Material type, 2023 to 2033
Figure 61: North America Market Value (US$ Billion) Analysis by Avalability, 2018 to 2033
Figure 62: North America Market Value Share (%) and BPS Analysis by Avalability, 2023 to 2033
Figure 63: North America Market Y-o-Y Growth (%) Projections by Avalability, 2023 to 2033
Figure 64: North America Market Value (US$ Billion) Analysis by Drug Modality, 2018 to 2033
Figure 65: North America Market Value Share (%) and BPS Analysis by Drug Modality, 2023 to 2033
Figure 66: North America Market Y-o-Y Growth (%) Projections by Drug Modality, 2023 to 2033
Figure 67: North America Market Value (US$ Billion) Analysis by Therapeutic class, 2018 to 2033
Figure 68: North America Market Value Share (%) and BPS Analysis by Therapeutic class, 2023 to 2033
Figure 69: North America Market Y-o-Y Growth (%) Projections by Therapeutic class, 2023 to 2033
Figure 70: North America Market Value (US$ Billion) Analysis by Neurological Drugs, 2018 to 2033
Figure 71: North America Market Value Share (%) and BPS Analysis by Neurological Drugs, 2023 to 2033
Figure 72: North America Market Y-o-Y Growth (%) Projections by Neurological Drugs, 2023 to 2033
Figure 73: North America Market Attractiveness by Product type, 2023 to 2033
Figure 74: North America Market Attractiveness by Functionality, 2023 to 2033
Figure 75: North America Market Attractiveness by Material type, 2023 to 2033
Figure 76: North America Market Attractiveness by Avalability, 2023 to 2033
Figure 77: North America Market Attractiveness by Drug Modality, 2023 to 2033
Figure 78: North America Market Attractiveness by Therapeutic class, 2023 to 2033
Figure 79: North America Market Attractiveness by Neurological Drugs, 2023 to 2033
Figure 80: North America Market Attractiveness by Country, 2023 to 2033
Figure 81: Latin America Market Value (US$ Billion) by Product type, 2023 to 2033
Figure 82: Latin America Market Value (US$ Billion) by Functionality, 2023 to 2033
Figure 83: Latin America Market Value (US$ Billion) by Material type, 2023 to 2033
Figure 84: Latin America Market Value (US$ Billion) by Avalability, 2023 to 2033
Figure 85: Latin America Market Value (US$ Billion) by Drug Modality, 2023 to 2033
Figure 86: Latin America Market Value (US$ Billion) by Therapeutic class, 2023 to 2033
Figure 87: Latin America Market Value (US$ Billion) by Neurological Drugs, 2023 to 2033
Figure 88: Latin America Market Value (US$ Billion) by Country, 2023 to 2033
Figure 89: Latin America Market Value (US$ Billion) Analysis by Country, 2018 to 2033
Figure 90: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 91: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 92: Latin America Market Value (US$ Billion) Analysis by Product type, 2018 to 2033
Figure 93: Latin America Market Value Share (%) and BPS Analysis by Product type, 2023 to 2033
Figure 94: Latin America Market Y-o-Y Growth (%) Projections by Product type, 2023 to 2033
Figure 95: Latin America Market Value (US$ Billion) Analysis by Functionality, 2018 to 2033
Figure 96: Latin America Market Value Share (%) and BPS Analysis by Functionality, 2023 to 2033
Figure 97: Latin America Market Y-o-Y Growth (%) Projections by Functionality, 2023 to 2033
Figure 98: Latin America Market Value (US$ Billion) Analysis by Material type, 2018 to 2033
Figure 99: Latin America Market Value Share (%) and BPS Analysis by Material type, 2023 to 2033
Figure 100: Latin America Market Y-o-Y Growth (%) Projections by Material type, 2023 to 2033
Figure 101: Latin America Market Value (US$ Billion) Analysis by Avalability, 2018 to 2033
Figure 102: Latin America Market Value Share (%) and BPS Analysis by Avalability, 2023 to 2033
Figure 103: Latin America Market Y-o-Y Growth (%) Projections by Avalability, 2023 to 2033
Figure 104: Latin America Market Value (US$ Billion) Analysis by Drug Modality, 2018 to 2033
Figure 105: Latin America Market Value Share (%) and BPS Analysis by Drug Modality, 2023 to 2033
Figure 106: Latin America Market Y-o-Y Growth (%) Projections by Drug Modality, 2023 to 2033
Figure 107: Latin America Market Value (US$ Billion) Analysis by Therapeutic class, 2018 to 2033
Figure 108: Latin America Market Value Share (%) and BPS Analysis by Therapeutic class, 2023 to 2033
Figure 109: Latin America Market Y-o-Y Growth (%) Projections by Therapeutic class, 2023 to 2033
Figure 110: Latin America Market Value (US$ Billion) Analysis by Neurological Drugs, 2018 to 2033
Figure 111: Latin America Market Value Share (%) and BPS Analysis by Neurological Drugs, 2023 to 2033
Figure 112: Latin America Market Y-o-Y Growth (%) Projections by Neurological Drugs, 2023 to 2033
Figure 113: Latin America Market Attractiveness by Product type, 2023 to 2033
Figure 114: Latin America Market Attractiveness by Functionality, 2023 to 2033
Figure 115: Latin America Market Attractiveness by Material type, 2023 to 2033
Figure 116: Latin America Market Attractiveness by Avalability, 2023 to 2033
Figure 117: Latin America Market Attractiveness by Drug Modality, 2023 to 2033
Figure 118: Latin America Market Attractiveness by Therapeutic class, 2023 to 2033
Figure 119: Latin America Market Attractiveness by Neurological Drugs, 2023 to 2033
Figure 120: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 121: Western Europe Market Value (US$ Billion) by Product type, 2023 to 2033
Figure 122: Western Europe Market Value (US$ Billion) by Functionality, 2023 to 2033
Figure 123: Western Europe Market Value (US$ Billion) by Material type, 2023 to 2033
Figure 124: Western Europe Market Value (US$ Billion) by Avalability, 2023 to 2033
Figure 125: Western Europe Market Value (US$ Billion) by Drug Modality, 2023 to 2033
Figure 126: Western Europe Market Value (US$ Billion) by Therapeutic class, 2023 to 2033
Figure 127: Western Europe Market Value (US$ Billion) by Neurological Drugs, 2023 to 2033
Figure 128: Western Europe Market Value (US$ Billion) by Country, 2023 to 2033
Figure 129: Western Europe Market Value (US$ Billion) Analysis by Country, 2018 to 2033
Figure 130: Western Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 131: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 132: Western Europe Market Value (US$ Billion) Analysis by Product type, 2018 to 2033
Figure 133: Western Europe Market Value Share (%) and BPS Analysis by Product type, 2023 to 2033
Figure 134: Western Europe Market Y-o-Y Growth (%) Projections by Product type, 2023 to 2033
Figure 135: Western Europe Market Value (US$ Billion) Analysis by Functionality, 2018 to 2033
Figure 136: Western Europe Market Value Share (%) and BPS Analysis by Functionality, 2023 to 2033
Figure 137: Western Europe Market Y-o-Y Growth (%) Projections by Functionality, 2023 to 2033
Figure 138: Western Europe Market Value (US$ Billion) Analysis by Material type, 2018 to 2033
Figure 139: Western Europe Market Value Share (%) and BPS Analysis by Material type, 2023 to 2033
Figure 140: Western Europe Market Y-o-Y Growth (%) Projections by Material type, 2023 to 2033
Figure 141: Western Europe Market Value (US$ Billion) Analysis by Avalability, 2018 to 2033
Figure 142: Western Europe Market Value Share (%) and BPS Analysis by Avalability, 2023 to 2033
Figure 143: Western Europe Market Y-o-Y Growth (%) Projections by Avalability, 2023 to 2033
Figure 144: Western Europe Market Value (US$ Billion) Analysis by Drug Modality, 2018 to 2033
Figure 145: Western Europe Market Value Share (%) and BPS Analysis by Drug Modality, 2023 to 2033
Figure 146: Western Europe Market Y-o-Y Growth (%) Projections by Drug Modality, 2023 to 2033
Figure 147: Western Europe Market Value (US$ Billion) Analysis by Therapeutic class, 2018 to 2033
Figure 148: Western Europe Market Value Share (%) and BPS Analysis by Therapeutic class, 2023 to 2033
Figure 149: Western Europe Market Y-o-Y Growth (%) Projections by Therapeutic class, 2023 to 2033
Figure 150: Western Europe Market Value (US$ Billion) Analysis by Neurological Drugs, 2018 to 2033
Figure 151: Western Europe Market Value Share (%) and BPS Analysis by Neurological Drugs, 2023 to 2033
Figure 152: Western Europe Market Y-o-Y Growth (%) Projections by Neurological Drugs, 2023 to 2033
Figure 153: Western Europe Market Attractiveness by Product type, 2023 to 2033
Figure 154: Western Europe Market Attractiveness by Functionality, 2023 to 2033
Figure 155: Western Europe Market Attractiveness by Material type, 2023 to 2033
Figure 156: Western Europe Market Attractiveness by Avalability, 2023 to 2033
Figure 157: Western Europe Market Attractiveness by Drug Modality, 2023 to 2033
Figure 158: Western Europe Market Attractiveness by Therapeutic class, 2023 to 2033
Figure 159: Western Europe Market Attractiveness by Neurological Drugs, 2023 to 2033
Figure 160: Western Europe Market Attractiveness by Country, 2023 to 2033
Figure 161: Eastern Europe Market Value (US$ Billion) by Product type, 2023 to 2033
Figure 162: Eastern Europe Market Value (US$ Billion) by Functionality, 2023 to 2033
Figure 163: Eastern Europe Market Value (US$ Billion) by Material type, 2023 to 2033
Figure 164: Eastern Europe Market Value (US$ Billion) by Avalability, 2023 to 2033
Figure 165: Eastern Europe Market Value (US$ Billion) by Drug Modality, 2023 to 2033
Figure 166: Eastern Europe Market Value (US$ Billion) by Therapeutic class, 2023 to 2033
Figure 167: Eastern Europe Market Value (US$ Billion) by Neurological Drugs, 2023 to 2033
Figure 168: Eastern Europe Market Value (US$ Billion) by Country, 2023 to 2033
Figure 169: Eastern Europe Market Value (US$ Billion) Analysis by Country, 2018 to 2033
Figure 170: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 171: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 172: Eastern Europe Market Value (US$ Billion) Analysis by Product type, 2018 to 2033
Figure 173: Eastern Europe Market Value Share (%) and BPS Analysis by Product type, 2023 to 2033
Figure 174: Eastern Europe Market Y-o-Y Growth (%) Projections by Product type, 2023 to 2033
Figure 175: Eastern Europe Market Value (US$ Billion) Analysis by Functionality, 2018 to 2033
Figure 176: Eastern Europe Market Value Share (%) and BPS Analysis by Functionality, 2023 to 2033
Figure 177: Eastern Europe Market Y-o-Y Growth (%) Projections by Functionality, 2023 to 2033
Figure 178: Eastern Europe Market Value (US$ Billion) Analysis by Material type, 2018 to 2033
Figure 179: Eastern Europe Market Value Share (%) and BPS Analysis by Material type, 2023 to 2033
Figure 180: Eastern Europe Market Y-o-Y Growth (%) Projections by Material type, 2023 to 2033
Figure 181: Eastern Europe Market Value (US$ Billion) Analysis by Avalability, 2018 to 2033
Figure 182: Eastern Europe Market Value Share (%) and BPS Analysis by Avalability, 2023 to 2033
Figure 183: Eastern Europe Market Y-o-Y Growth (%) Projections by Avalability, 2023 to 2033
Figure 184: Eastern Europe Market Value (US$ Billion) Analysis by Drug Modality, 2018 to 2033
Figure 185: Eastern Europe Market Value Share (%) and BPS Analysis by Drug Modality, 2023 to 2033
Figure 186: Eastern Europe Market Y-o-Y Growth (%) Projections by Drug Modality, 2023 to 2033
Figure 187: Eastern Europe Market Value (US$ Billion) Analysis by Therapeutic class, 2018 to 2033
Figure 188: Eastern Europe Market Value Share (%) and BPS Analysis by Therapeutic class, 2023 to 2033
Figure 189: Eastern Europe Market Y-o-Y Growth (%) Projections by Therapeutic class, 2023 to 2033
Figure 190: Eastern Europe Market Value (US$ Billion) Analysis by Neurological Drugs, 2018 to 2033
Figure 191: Eastern Europe Market Value Share (%) and BPS Analysis by Neurological Drugs, 2023 to 2033
Figure 192: Eastern Europe Market Y-o-Y Growth (%) Projections by Neurological Drugs, 2023 to 2033
Figure 193: Eastern Europe Market Attractiveness by Product type, 2023 to 2033
Figure 194: Eastern Europe Market Attractiveness by Functionality, 2023 to 2033
Figure 195: Eastern Europe Market Attractiveness by Material type, 2023 to 2033
Figure 196: Eastern Europe Market Attractiveness by Avalability, 2023 to 2033
Figure 197: Eastern Europe Market Attractiveness by Drug Modality, 2023 to 2033
Figure 198: Eastern Europe Market Attractiveness by Therapeutic class, 2023 to 2033
Figure 199: Eastern Europe Market Attractiveness by Neurological Drugs, 2023 to 2033
Figure 200: Eastern Europe Market Attractiveness by Country, 2023 to 2033
Figure 201: South Asia and Pacific Market Value (US$ Billion) by Product type, 2023 to 2033
Figure 202: South Asia and Pacific Market Value (US$ Billion) by Functionality, 2023 to 2033
Figure 203: South Asia and Pacific Market Value (US$ Billion) by Material type, 2023 to 2033
Figure 204: South Asia and Pacific Market Value (US$ Billion) by Avalability, 2023 to 2033
Figure 205: South Asia and Pacific Market Value (US$ Billion) by Drug Modality, 2023 to 2033
Figure 206: South Asia and Pacific Market Value (US$ Billion) by Therapeutic class, 2023 to 2033
Figure 207: South Asia and Pacific Market Value (US$ Billion) by Neurological Drugs, 2023 to 2033
Figure 208: South Asia and Pacific Market Value (US$ Billion) by Country, 2023 to 2033
Figure 209: South Asia and Pacific Market Value (US$ Billion) Analysis by Country, 2018 to 2033
Figure 210: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 211: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 212: South Asia and Pacific Market Value (US$ Billion) Analysis by Product type, 2018 to 2033
Figure 213: South Asia and Pacific Market Value Share (%) and BPS Analysis by Product type, 2023 to 2033
Figure 214: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Product type, 2023 to 2033
Figure 215: South Asia and Pacific Market Value (US$ Billion) Analysis by Functionality, 2018 to 2033
Figure 216: South Asia and Pacific Market Value Share (%) and BPS Analysis by Functionality, 2023 to 2033
Figure 217: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Functionality, 2023 to 2033
Figure 218: South Asia and Pacific Market Value (US$ Billion) Analysis by Material type, 2018 to 2033
Figure 219: South Asia and Pacific Market Value Share (%) and BPS Analysis by Material type, 2023 to 2033
Figure 220: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Material type, 2023 to 2033
Figure 221: South Asia and Pacific Market Value (US$ Billion) Analysis by Avalability, 2018 to 2033
Figure 222: South Asia and Pacific Market Value Share (%) and BPS Analysis by Avalability, 2023 to 2033
Figure 223: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Avalability, 2023 to 2033
Figure 224: South Asia and Pacific Market Value (US$ Billion) Analysis by Drug Modality, 2018 to 2033
Figure 225: South Asia and Pacific Market Value Share (%) and BPS Analysis by Drug Modality, 2023 to 2033
Figure 226: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Drug Modality, 2023 to 2033
Figure 227: South Asia and Pacific Market Value (US$ Billion) Analysis by Therapeutic class, 2018 to 2033
Figure 228: South Asia and Pacific Market Value Share (%) and BPS Analysis by Therapeutic class, 2023 to 2033
Figure 229: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Therapeutic class, 2023 to 2033
Figure 230: South Asia and Pacific Market Value (US$ Billion) Analysis by Neurological Drugs, 2018 to 2033
Figure 231: South Asia and Pacific Market Value Share (%) and BPS Analysis by Neurological Drugs, 2023 to 2033
Figure 232: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Neurological Drugs, 2023 to 2033
Figure 233: South Asia and Pacific Market Attractiveness by Product type, 2023 to 2033
Figure 234: South Asia and Pacific Market Attractiveness by Functionality, 2023 to 2033
Figure 235: South Asia and Pacific Market Attractiveness by Material type, 2023 to 2033
Figure 236: South Asia and Pacific Market Attractiveness by Avalability, 2023 to 2033
Figure 237: South Asia and Pacific Market Attractiveness by Drug Modality, 2023 to 2033
Figure 238: South Asia and Pacific Market Attractiveness by Therapeutic class, 2023 to 2033
Figure 239: South Asia and Pacific Market Attractiveness by Neurological Drugs, 2023 to 2033
Figure 240: South Asia and Pacific Market Attractiveness by Country, 2023 to 2033
Figure 241: East Asia Market Value (US$ Billion) by Product type, 2023 to 2033
Figure 242: East Asia Market Value (US$ Billion) by Functionality, 2023 to 2033
Figure 243: East Asia Market Value (US$ Billion) by Material type, 2023 to 2033
Figure 244: East Asia Market Value (US$ Billion) by Avalability, 2023 to 2033
Figure 245: East Asia Market Value (US$ Billion) by Drug Modality, 2023 to 2033
Figure 246: East Asia Market Value (US$ Billion) by Therapeutic class, 2023 to 2033
Figure 247: East Asia Market Value (US$ Billion) by Neurological Drugs, 2023 to 2033
Figure 248: East Asia Market Value (US$ Billion) by Country, 2023 to 2033
Figure 249: East Asia Market Value (US$ Billion) Analysis by Country, 2018 to 2033
Figure 250: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 251: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 252: East Asia Market Value (US$ Billion) Analysis by Product type, 2018 to 2033
Figure 253: East Asia Market Value Share (%) and BPS Analysis by Product type, 2023 to 2033
Figure 254: East Asia Market Y-o-Y Growth (%) Projections by Product type, 2023 to 2033
Figure 255: East Asia Market Value (US$ Billion) Analysis by Functionality, 2018 to 2033
Figure 256: East Asia Market Value Share (%) and BPS Analysis by Functionality, 2023 to 2033
Figure 257: East Asia Market Y-o-Y Growth (%) Projections by Functionality, 2023 to 2033
Figure 258: East Asia Market Value (US$ Billion) Analysis by Material type, 2018 to 2033
Figure 259: East Asia Market Value Share (%) and BPS Analysis by Material type, 2023 to 2033
Figure 260: East Asia Market Y-o-Y Growth (%) Projections by Material type, 2023 to 2033
Figure 261: East Asia Market Value (US$ Billion) Analysis by Avalability, 2018 to 2033
Figure 262: East Asia Market Value Share (%) and BPS Analysis by Avalability, 2023 to 2033
Figure 263: East Asia Market Y-o-Y Growth (%) Projections by Avalability, 2023 to 2033
Figure 264: East Asia Market Value (US$ Billion) Analysis by Drug Modality, 2018 to 2033
Figure 265: East Asia Market Value Share (%) and BPS Analysis by Drug Modality, 2023 to 2033
Figure 266: East Asia Market Y-o-Y Growth (%) Projections by Drug Modality, 2023 to 2033
Figure 267: East Asia Market Value (US$ Billion) Analysis by Therapeutic class, 2018 to 2033
Figure 268: East Asia Market Value Share (%) and BPS Analysis by Therapeutic class, 2023 to 2033
Figure 269: East Asia Market Y-o-Y Growth (%) Projections by Therapeutic class, 2023 to 2033
Figure 270: East Asia Market Value (US$ Billion) Analysis by Neurological Drugs, 2018 to 2033
Figure 271: East Asia Market Value Share (%) and BPS Analysis by Neurological Drugs, 2023 to 2033
Figure 272: East Asia Market Y-o-Y Growth (%) Projections by Neurological Drugs, 2023 to 2033
Figure 273: East Asia Market Attractiveness by Product type, 2023 to 2033
Figure 274: East Asia Market Attractiveness by Functionality, 2023 to 2033
Figure 275: East Asia Market Attractiveness by Material type, 2023 to 2033
Figure 276: East Asia Market Attractiveness by Avalability, 2023 to 2033
Figure 277: East Asia Market Attractiveness by Drug Modality, 2023 to 2033
Figure 278: East Asia Market Attractiveness by Therapeutic class, 2023 to 2033
Figure 279: East Asia Market Attractiveness by Neurological Drugs, 2023 to 2033
Figure 280: East Asia Market Attractiveness by Country, 2023 to 2033
Figure 281: Middle East and Africa Market Value (US$ Billion) by Product type, 2023 to 2033
Figure 282: Middle East and Africa Market Value (US$ Billion) by Functionality, 2023 to 2033
Figure 283: Middle East and Africa Market Value (US$ Billion) by Material type, 2023 to 2033
Figure 284: Middle East and Africa Market Value (US$ Billion) by Avalability, 2023 to 2033
Figure 285: Middle East and Africa Market Value (US$ Billion) by Drug Modality, 2023 to 2033
Figure 286: Middle East and Africa Market Value (US$ Billion) by Therapeutic class, 2023 to 2033
Figure 287: Middle East and Africa Market Value (US$ Billion) by Neurological Drugs, 2023 to 2033
Figure 288: Middle East and Africa Market Value (US$ Billion) by Country, 2023 to 2033
Figure 289: Middle East and Africa Market Value (US$ Billion) Analysis by Country, 2018 to 2033
Figure 290: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 291: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 292: Middle East and Africa Market Value (US$ Billion) Analysis by Product type, 2018 to 2033
Figure 293: Middle East and Africa Market Value Share (%) and BPS Analysis by Product type, 2023 to 2033
Figure 294: Middle East and Africa Market Y-o-Y Growth (%) Projections by Product type, 2023 to 2033
Figure 295: Middle East and Africa Market Value (US$ Billion) Analysis by Functionality, 2018 to 2033
Figure 296: Middle East and Africa Market Value Share (%) and BPS Analysis by Functionality, 2023 to 2033
Figure 297: Middle East and Africa Market Y-o-Y Growth (%) Projections by Functionality, 2023 to 2033
Figure 298: Middle East and Africa Market Value (US$ Billion) Analysis by Material type, 2018 to 2033
Figure 299: Middle East and Africa Market Value Share (%) and BPS Analysis by Material type, 2023 to 2033
Figure 300: Middle East and Africa Market Y-o-Y Growth (%) Projections by Material type, 2023 to 2033
Figure 301: Middle East and Africa Market Value (US$ Billion) Analysis by Avalability, 2018 to 2033
Figure 302: Middle East and Africa Market Value Share (%) and BPS Analysis by Avalability, 2023 to 2033
Figure 303: Middle East and Africa Market Y-o-Y Growth (%) Projections by Avalability, 2023 to 2033
Figure 304: Middle East and Africa Market Value (US$ Billion) Analysis by Drug Modality, 2018 to 2033
Figure 305: Middle East and Africa Market Value Share (%) and BPS Analysis by Drug Modality, 2023 to 2033
Figure 306: Middle East and Africa Market Y-o-Y Growth (%) Projections by Drug Modality, 2023 to 2033
Figure 307: Middle East and Africa Market Value (US$ Billion) Analysis by Therapeutic class, 2018 to 2033
Figure 308: Middle East and Africa Market Value Share (%) and BPS Analysis by Therapeutic class, 2023 to 2033
Figure 309: Middle East and Africa Market Y-o-Y Growth (%) Projections by Therapeutic class, 2023 to 2033
Figure 310: Middle East and Africa Market Value (US$ Billion) Analysis by Neurological Drugs, 2018 to 2033
Figure 311: Middle East and Africa Market Value Share (%) and BPS Analysis by Neurological Drugs, 2023 to 2033
Figure 312: Middle East and Africa Market Y-o-Y Growth (%) Projections by Neurological Drugs, 2023 to 2033
Figure 313: Middle East and Africa Market Attractiveness by Product type, 2023 to 2033
Figure 314: Middle East and Africa Market Attractiveness by Functionality, 2023 to 2033
Figure 315: Middle East and Africa Market Attractiveness by Material type, 2023 to 2033
Figure 316: Middle East and Africa Market Attractiveness by Avalability, 2023 to 2033
Figure 317: Middle East and Africa Market Attractiveness by Drug Modality, 2023 to 2033
Figure 318: Middle East and Africa Market Attractiveness by Therapeutic class, 2023 to 2033
Figure 319: Middle East and Africa Market Attractiveness by Neurological Drugs, 2023 to 2033
Figure 320: Middle East and Africa Market Attractiveness by Country, 2023 to 2033
